Nicole joined Arboretum as a venture partner in 2023 and serves on the Allay board of directors. Previously, Nicole spent over 20 years as a investing partner with Domain Associates, a venture capital firm focused in the life science sector. With extensive experience in both public and private investing, Nicole is currently a board director at Esperion Therapeutics and was a former board observer at Iterum Therapeutics. 

Past board memberships include Achillion Pharmaceuticals (sold to Alexion), Calixa Therapeutics (sold to Cubist Pharmaceuticals),  Celator Pharmaceuticals (sold to Jazz Pharmaceuticals), Cerexa (sold to Forest Laboratories), Durata Therapeutics (sold to Actavis), Marinus Pharmaceuticals, Onyx Pharmaceuticals and VentiRx Pharmaceuticals (sold to Celgene).

Prior to Domain, Nicole was senior vice president at Rothschild Asset Management, Inc. where she had responsibility for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited. She received her B.A. in mathematics and her MBA in finance from the University of Rochester.